Early Success in a Human Embryonic Stem Cell Trial to Treat Blindness Date: January 24, 2012 Client: Advanced Cell Technology, Inc. Summary: For the researchers at UCLA's Jules Stein Eye Institute who launched the first-ever study to show that human embryonic stem cells may help reverse patients' disease, the history-making day began at 4:30 a.m. It was an early morning wake-up call, to be sure, but a necessary one to prepare for the groundbreaking work that lay ahead. On July 12, 2011, the scientists injected retinal cells derived from embryonic stem cells into the eyes of two patients suffering from progressive blindness, and the results announced Monday suggest that the treatment has changed their lives.
		New York State Department of Health Certifies AssureRx Health's Laboratory Date: January 24, 2012 Client: AssureRx Health, Inc. Summary: MASON, OHIO Jan. 24, 2012 - AssureRx Health, Inc., announced today that its laboratory has been certified by the New York State Department of Health, ensuring that patients throughout New York State have access to the GeneSightRx testing program through their personal prescribing clinician. With the approval from New York State, the AssureRx Health laboratory is now certified to analyze DNA samples for pharmacogenomic testing in all 50 U.S. states.
		$1.6 Billion Raised by U.S. Companies Through At-the-Market (ATM) Offerings in Third Quarter of 2011, Brinson Patrick Reports Date: January 24, 2012 Client: Brinson Patrick Summary: NEW YORK, Jan. 24, 2012 - Brinson Patrick Securities Corporation, a boutique investment bank specializing in at-the-market (ATM) offerings, announced today that U.S. companies raised $1.6 billion through the activity of 62 ATM offerings of common stock across 20 industries in the third quarter of last year. This dollar amount represented a 23 percent decrease in the amount of capital companies raised via ATMs compared to the third quarter of 2010.
		Stem Cell Treatment for Eye Diseases Shows Promise Date: January 23, 2012 Client: Advanced Cell Technology, Inc. Summary: LOS ANGELES - A treatment for eye diseases that is derived from human embryonic stem cells might have improved the vision of two patients, bolstering the beleaguered field, researchers reported Monday.
		ACT Publishes First Report of Embryonic Stem Cell (ESC)-Derived Cells Transplanted Into Patients Date: January 23, 2012 Client: Advanced Cell Technology, Inc. Summary: MARLBOROUGH, Mass., Jan 23, 2012 -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that Phase 1/2 clinical data published in The Lancet as an early online publication demonstrate the safety of ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells for the treatment of Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD). Results were reported for two patients, the first in each of the Phase 1/2 clinical trials. In addition to showing no adverse safety issues, structural evidence confirmed that the hESC-derived cells survived and continued to persist during the study period reported. Both patients had measurable improvements in their vision that persisted for more than four months.
		ACT Announces Europe's First Human Embryonic Stem Cell Transplant in Patient with Stargardt's Disease Date: January 23, 2012 Client: Advanced Cell Technology, Inc. Summary: MARLBOROUGH, Mass., Jan 23, 2012 -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, Jan. 20, at the Moorfields Eye Hospital in London by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The patient successfully underwent the procedure without any complications. ACT and Moorfields Eye Hospital received clearance in September from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) to begin this trial in Europe.
		AssureRx Health Launches New Technology Platform to Enhance GeneSightRx and Fast-Track New Products Date: January 17, 2012 Client: AssureRx Health, Inc. Summary: CINCINNATI, Jan. 17, 2012 - AssureRx Health, Inc., today announced the release of GeneSightRx 1.8, a pharmacogenomic testing program helping behavioral health clinicians select medications for their patients using genetic information, peer-reviewed research and approved drug labeling. The enhancements include the addition of six new psychotropic medications to the current panel of 26 medications, expanded support for mobile devices, and new capabilities to fast-track research discoveries into clinical practice.
		Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration Date: January 17, 2012 Client: Advanced Cell Technology, Inc. Summary: MARLBOROUGH, Mass., Jan 17, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the Phase 1/2 clinical trial for dry age-related macular degeneration (dry AMD) using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
		Shopping for Financing "At-the-Market" Date: January 15, 2012 Client: Brinson Patrick Summary: Publicly traded life science companies are constantly searching for new sources of capital to fund their activities. Companies generally follow a traditional approach employing conventional financing vehicles such as secondary offerings, registered directs, and private investments in public equities (PIPEs).
		Receptos Achieves Milestone Under License of G-Protein Coupled Receptor Crystal Structure Determination Technology Date: January 10, 2012 Client: Receptos Inc. Summary: SAN DIEGO, Calif., January 10, 2012 - Receptos Inc. today announced the successful achievement of the technology transfer milestone under its license and technology transfer deal with Janssen Pharmaceuticals, Inc. (formerly Ortho-McNeil Janssen Pharmaceuticals, Inc.), for Receptos' breakthrough GPCR crystal structure determination technology.
		FDA Accepts Resubmission of Lorcaserin New Drug Application Date: January 10, 2012 Client: Arena Pharmaceuticals, Inc. Summary: SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 10, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has accepted for filing and review Arena's resubmission of the New Drug Application (NDA) for lorcaserin. The FDA considers the resubmission a complete, class 2 response, and assigned a new Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.
		Incyte comes of age with JAK inhibitor approval Date: January 10, 2012 Client: S*BIO Summary: There were several reasons to celebrate on November 16 when the US Food and Drug Administration (FDA) approved Jakafi (ruxolitinib), a small-molecule drug against the rare blood cancer myelofibrosis and other myeloproliferative disorders. Not only is Jakafi the first treatment approved against myelofibrosis and similar neoplasms, but it is also Incyte's first drug to market, one that validates a novel mechanism of action in cancer no less-blocking the Janus-kinases JAK1 and JAK2. The small-molecule development program also exemplifies a rapid development time-six years after an activating mutation in JAK2 was first identified in this cancer; and, in this case, Incyte's embrace of patient-reported outcome tools in the trial design was key in facilitating approval, according to the FDA's Richard Pazdur (Box 1). Other companies developing JAK inhibitors against myelofibrosis and two related myeloproliferative disorders, polycythemia vera and essential thrombocythemia, will now be pushing to get a slice of the market (Table 1).
		Sernova to Present Company and Clinical Update at Biotech Showcase Date: January 9, 2012 Client: Sernova Corp. Summary: LONDON, ONTARIO--(Marketwire -- Jan. 9, 2012) - Sernova Corp. (TSX-V: SVA), today announced that Dr. Philip Toleikis, Ph.D., President and CEO of Sernova, will present an update on the company's technology and its plans to initiate patient enrollment in a Phase I/II clinical trial for its Cell Pouch System at 11 a.m. PST, Monday, Jan. 9, at the Biotech Showcase. The conference will be held at Parc 55 Wyndham Union Square Hotel in San Francisco.
		MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support Date: January 9, 2012 Client: MolecularHealth Summary: NEW YORK, Jan. 9, 2012 - MolecularHealth, a clinico-molecular informatics company, today announced the commercialization and planned roll-out of two next generation product lines that translate patient-specific molecular and genomic data, clinical history and published scientific evidence into safer, more effective drug choices for patients.
		Sutro Announces Newly Formed Scientific Advisory Board Date: January 9, 2012 Client: Sutro Biopharma Summary: SAN FRANCISCO, Jan. 7, 2012 - Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that it has appointed James A. Wells, Ph.D., and James R. Swartz, Sc.D., to its newly formed scientific advisory board (SAB). Prof. Wells will serve as Chairman of the SAB.
		Gene Security Network Announces Completion of $20 Million Financing Round, Change of Company Name to Natera Date: January 6, 2012 Client: Gene Security Network Inc. Summary: REDWOOD CITY, Calif., January 6, 2011 -- Gene Security Network Inc. (GSN) today announced the completion of a $20 million financing round, as well as the change of the company's name to Natera, Inc. The financing round was led by Lightspeed Venture Partners, which is joined in the current round by Claremont Creek Ventures and Sequoia Capital.
		Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference Date: January 6, 2012 Client: Reata Pharmaceuticals, Inc. Summary: IRVING, Texas, January 6, 2012 - Reata Pharmaceuticals, Inc. today announced that Warren Huff, President and CEO, will present a company overview at the 30th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 10, at 10:00 a.m. PST in the Elizabethan C/D Room at the Westin St. Francis Hotel in San Francisco, CA.
		Probiodrug AG to Present at the 30th JP Morgan Annual Healthcare Conference Date: January 6, 2012 Client: Probiodrug AG Summary: HALLE/SAALE, Germany, Jan. 6, 2012 - Probiodrug AG today announced that Konrad Glund, Ph.D., Chief Executive Officer of Probiodrug, will present at the 30th JP Morgan Annual Healthcare Conference at 8:30 a.m. PST, Wednesday, Jan. 11, at the Westin St. Francis Hotel in San Francisco. Dr Glund will provide an overview of the company and discuss progress in its lead clinical program, PQ912, the first glutaminyl cyclase inhibitor to enter clinical development for the treatment of Alzheimer's disease.
		Brinson Patrick Securities Establishes Equity Research Department with Addition of Analyst Michael Higgins Date: January 5, 2012 Client: Brinson Patrick Securities Corporation Summary: NEW YORK, Jan. 5, 2012 - Brinson Patrick Securities Corporation, a boutique investment bank that focuses specifically on at-the-market (ATM) offerings, today announced the establishment of an equity research department, pending regulatory approval, with the hiring of Michael Higgins as a life sciences analyst. Higgins has joined Brinson Patrick from Rodman & Renshaw, LLC, where he was a managing director and senior specialty pharmaceuticals analyst.
		OrbusNeich's Genous Stent Achieves Good, Comparable Clinical Outcomes in Patients Discontinuing Dual Antiplatelet Therapy at 30 Days and at Six Months Date: January 5, 2012 Client: OrbusNeich Summary: HONG KONG, Jan. 5, 2012 - OrbusNeich today announced that 12-month follow-up data from a post-hoc analysis of the e-HEALING registry demonstrate that the company's Genous Stent achieves good, comparable clinical and safety outcomes in patients discontinuing dual antiplatelet therapy (DAPT) at 30 days and at six months. According to the study, clinical outcomes in patients treated with Genous were not associated with the duration of DAPT. The study has been published online in Catheterization and Cardiovascular Interventions.
		Regulus Therapeutics to Present microRNA Platform and Pipeline Updates at Two Leading Scientific Conferences Date: January 5, 2012 Client: Regulus Therapeutics Inc. Summary: LA JOLLA, Calif., Jan. 5, 2012 - Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data from its proprietary lead program targeting microRNA-33a/b (miR-33a/b), currently in preclinical development for the treatment of atherosclerosis, will be presented at the Keystone Symposium "Nucleic Acid Therapeutics: From Base Pairs to Bedsides" held Jan. 10-15, 2012, in Santa Fe, New Mexico. In addition, information from its preclinical oncology programs will be presented at the American Association for Cancer Research's (AACR) Noncoding RNAs and Cancer workshop held Jan. 8-11, 2012, in Miami, Florida.
		Healthfirst Health Plan Partners with MedAssurant in Commitment to Quality Outcomes Date: January 5, 2012 Client: MedAssurant, Inc. Summary: BOWIE, Md. - January 5, 2012 - MedAssurant, Inc., a leading provider of data-driven healthcare solutions, today announced that Healthfirst, Inc. will implement Star Advantage, MedAssurant's quality outcomes improvement solution that enables health plans to both better understand and meaningfully impact their CMS Five-Star Quality Ratings. Star Advantage leverages the nation's most widely used healthcare quality measurement system, large-scale healthcare dataset analytics, and a nationwide clinical operations infrastructure to proactively identify, and both efficiently and effectively resolve gaps in member quality outcomes.
		Arena Submits Response to FDA Complete Response Letter for Lorcaserin Date: January 3, 2012 Client: Arena Pharmaceuticals, Inc. Summary: SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 3, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that Arena has submitted its response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) following review of the lorcaserin New Drug Application (NDA). Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index, or BMI, > 30) or patients who are overweight (BMI > 27) and have at least one weight-related co-morbid condition. The companies expect that later this month the FDA will confirm acceptance of the response and assign a new Prescription Drug User Fee Act (PDUFA) date.
		Living creatively Date: January 2, 2012 Client: Brinson Patrick Summary: For small, early stage biotech companies,2012 could be the year of living creatively.
		Industrial Quantities of IPSCs Now Possible Date: January 1, 2012 Client: Cellular Dynamics International Summary: Stem cells can be used for biological research and drug discovery, or to create new tissue and regenerate damaged organs. However, bans on the use of embryonic stem cells and the need for industrial quantities of high-quality stem cell lines slowed progress in the field.